Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Frequently asked questions
What sector does PHARVARIS N.V. EO -12 (9EN) operate in?
PHARVARIS N.V. EO -12 belongs to the Healthcare sector and operates in the Biotechnology industry.
What is PHARVARIS N.V. EO -12 (9EN) current stock price?
As of the latest data, PHARVARIS N.V. EO -12 stock price is €28.30, with a previous close of €27.75. PHARVARIS N.V. EO -12 gained €0.55 in the last trading session, representing a 1.98% increase.
What is PHARVARIS N.V. EO -12 (9EN) current market capitalization?
PHARVARIS N.V. EO -12 market cap is approximately 1.99 billion.
What is PHARVARIS N.V. EO -12 (9EN) Earnings Per Share (EPS)?
The trailing EPS is -€2.62.
What is PHARVARIS N.V. EO -12 (9EN) EBITDA?
PHARVARIS N.V. EO -12 EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -50.61 million.
Does PHARVARIS N.V. EO -12 (9EN) pay dividends?
No. PHARVARIS N.V. EO -12 does not pay a dividend.
When is PHARVARIS N.V. EO -12 (9EN) next earnings report?
PHARVARIS N.V. EO -12 is expected to release its next earnings report on September 30, 2026.
What is PHARVARIS N.V. EO -12 (9EN) beta (volatility) score?
PHARVARIS N.V. EO -12 has a beta of -2.461, indicating lower volatility than the overall market.
